Saturday, December 4, 2021

FDA panel backs booster shot for J&J COVID-19 vaccine

Read Also:  Drug regulator says Europe must close vaccination gap to prevent COVID surge

A vial of Johnson & Johnson COVID-19 vaccine Bay Shore, NY. on display at South Shore University Hospital in

AP Photo / Mark Lenihan

WASHINGTON (AP) – A panel of US health advisors on Friday backed booster doses of Johnson & Johnson’s single-shot COVID-19 vaccine, saying they should be offered at least two months after vaccination.

J&J has asked the Food and Drug Administration for flexibility with its boosters, arguing that the extra dose adds significant protection only two months after the initial vaccination — but it may work better if people wait until six months later. Do it.

The FDA’s advisory panel voted unanimously that boosters should be offered without setting a firm time. The advisors cited growing concern that recipients of J&K vaccinations appear to be less safe than those who received the two-dose Pfizer or Moderna options – and most had received that single dose several months earlier.

The FDA isn’t bound by the vote, but its final decision could help expand the country’s booster campaign.

The government says all three US vaccines offer strong protection against hospitalization and death from COVID-19, and the priority is getting unvaccinated people the first shots. But there is a growing push to increase protection against “breakthrough” infections and the extra-infectious delta version of the coronavirus.

Booster doses of Pfizer’s vaccine began last month for people at high risk of COVID-19, and an FDA advisory panel has recommended a similar approach for Moderna recipients.


Nation World News Desk
Nation World News is the fastest emerging news website covering all the latest news, world’s top stories, science news entertainment sports cricket’s latest discoveries, new technology gadgets, politics news, and more.
Latest news
Related news
- Advertisement -